- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 03.03. | MAIA Biotechnology slides after pricing offering to raise $30M | 2 | Seeking Alpha | ||
| 03.03. | MAIA Biotechnology Prices $30 Mln Public Offering Of Shares At $1.50/shr; Stock Down | 2 | RTTNews | ||
| 03.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock | 183 | GlobeNewswire (Europe) | Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA"... ► Artikel lesen | |
| 02.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants | 124 | GlobeNewswire (Europe) | CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 24.02. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.02. | MAIA Biotechnology, Inc.: MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market | 349 | GlobeNewswire (Europe) | Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine... ► Artikel lesen | |
| 20.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.01. | MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | 485 | GlobeNewswire (Europe) | High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine... ► Artikel lesen | |
| 13.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | 332 | GlobeNewswire (Europe) | Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)... ► Artikel lesen | |
| 16.12.25 | MAIA Biotechnology announces $1.51M private placement | 2 | Seeking Alpha | ||
| 16.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces $1.51 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates | 231 | GlobeNewswire (Europe) | CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA),... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer | 444 | GlobeNewswire (Europe) | Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE... ► Artikel lesen | |
| 11.12.25 | MAIA Biotechnology, Inc.: MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential | 4 | GlobeNewswire (USA) | ||
| 10.12.25 | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.12.25 | MAIA Biotechnology, Inc.: MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach | 162 | GlobeNewswire (Europe) | CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) - The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade... ► Artikel lesen | |
| 01.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Directors | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 118,32 | -0,12 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ABBVIE | 178,80 | +0,56 % | Defensive Biotech-Wetten? Warum Amgen und AbbVie strukturell wachsen - kleiner Player Mesoblast im Fokus | ||
| ABBOTT LABORATORIES | 91,80 | +0,44 % | Abbott to close $21B Exact Sciences deal on March 23 | ||
| SCHOTT PHARMA | 12,960 | -1,97 % | SCHOTT PHARMA AG & CO KGAA im strukturellen Gleichgewicht | ||
| EDWARDS LIFESCIENCES | 72,10 | 0,00 % | Edwards Lifesciences Corp. Q4 Profit Falls | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) announced earnings for fourth quarter that Drops, from last yearThe company's earnings totaled $91.2 million, or $0.16 per share. This... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 23,900 | -2,85 % | Assembly Biosciences: "Wir erwarten ein weiteres starkes Jahr" | Der Virologieforscher Assembly Biosciences blickt nach einem entscheidenden Jahr 2025 auf eine positive Zukunft. Im jüngsten Geschäftsbericht wird eine Ausweitung der Pipeline angedeutet. Es könnte... ► Artikel lesen | |
| PENTIXAPHARM | 1,776 | -3,79 % | EQS-News: Pentixapharm Holding AG: Die Pentixapharm Holding AG veröffentlicht am 26. März 2026 den Finanzbericht für das Geschäftsjahr 2025 | EQS-News: Pentixapharm Holding AG
/ Schlagwort(e): Jahresbericht
Die Pentixapharm Holding AG veröffentlicht am 26. März 2026 den Finanzbericht für das Geschäftsjahr 2025 (News... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,556 | -1,98 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 134,85 | -0,74 % | Mizuho reiterates Axsome stock Outperform on Auvelity growth | ||
| MEDPACE | 391,50 | -0,03 % | Zelluna ASA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial | Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA... ► Artikel lesen | |
| ZEALAND PHARMA | 37,670 | -0,97 % | Zealand Pharma increases its share capital as a result of the exercise of employee warrants | ||
| UNITED THERAPEUTICS | 457,20 | +0,75 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| UCB | 242,80 | -0,61 % | UCB Full-year Profit, Sales Jump: Issues Upbeat Outlook | BRUSSELS (dpa-AFX) - UCB SA (UCBJY) on Thursday reported a 46% increase in full-year profit, supported by a 32% rise in sales.Profit before income taxes increased 57% to €1.822 billion from... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 388,80 | +0,49 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| BRIDGEBIO PHARMA | 60,14 | +1,38 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen MAIA BIOTECHNOLOGY INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,420 Euro und damit -4,38 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.